Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers

Experimental and Therapeutic Medicine

Volumn 4, Issue 2, 2012, Pages 231-236

  Rau, Kun Ming ^a,c   Huang, Chao Cheng ^b,c   Chiu, Tai Jan ^a   Chen, Yen Yang ^a   Lu, Chien Chang ^b   Liu, Chien Ting ^a   Pei, Sung Nan ^a   Wei, Yu Ching ^b  

^a Division of Hematology Oncology   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Angiogenesis; Breast cancer; CD105; Endoglin; Hormone receptor; Neovascularization; Prognosis

Indexed keywords

ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; CD34 ANTIGEN; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PARAFFIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG TARGETING; ENDOTHELIUM; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROVASCULATURE; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); OVERALL SURVIVAL; PROTEIN EXPRESSION; STAINING; STATISTICAL SIGNIFICANCE; SURVIVAL PREDICTION; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

EID: 84862642954     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.594     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Cianfrocca M and Gradishar W: New molecular classifications of breast cancer. CA Cancer J Clin 59: 303-313, 2009.
3. Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989.
4. Gasparini G: Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur J Cancer 32A: 2485-2493, 1996.
5. Uzzan B, Nicolas P, Cucherat M and Perret GY: Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64: 2941-2955, 2004.
6. Nico B, Benagiano V, Mangieri D, Maruotti N, Vacca A and Ribatti D: Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol 23: 601-607, 2008.
7. Fox SB, Gasparini G and Harris AL: Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2: 278-289, 2001.
8. Woodfin A, Voisin MB and Nourshargh S: PECAM-1: a multifunctional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol 27: 2514-2523, 2007.
9. Mineo TC, Ambrogi V, Baldi A, et al: Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 57: 591-597, 2004.
10. da Silva BB, Lopes-Costa PV, dos Santos AR, et al: Comparison of three vascular endothelial markers in the evaluation of microvessel density in breast cancer. Eur J Gynaecol Oncol 30: 285-288, 2009.
11. Tanaka F, Otake Y, Yanagihara K, et al: Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7: 3410-3415, 2001.
12. Fonsatti E, Del Vecchio L, Altomonte M, et al: Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 188: 1-7, 2001.
13. Kumar S, Ghellal A, Li C, et al: Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59: 856-861, 1999.
14. Dallas NA, Samuel S, Xia L, et al: Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14: 1931-1937, 2008.
15. Yao Y, Kubota T, Takeuchi H and Sato K: Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 25: 201-206, 2005.
16. Elliott RL and Blobe GC: Role of transforming growth factor beta in human cancer. J Clin Oncol 23: 2078-2093, 2005.
17. Yamamoto T, Kozawa O, Tanabe K, et al: Involvement of p38 MAP kinase in TGF-beta-stimulated VEGF synthesis in aortic smooth muscle cells. J Cell Biochem 82: 591-598, 2001.
18. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C and Kumar S: CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 14: 55-64, 2000.
19. Seon BK, Haba A, Matsuno F, et al: Endoglin-targeted cancer therapy. Curr Drug Deliv 8: 135-143, 2011.
20. Marinho A, Soares R, Ferro J, Lacerda M and Schmitt FC: Angiogenesis in breast cancer is related to age but not to other prognostic parameters. Pathol Res Pract 193: 267-273, 1997.
21. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
22. Liedtke C and Kiesel L: Current issues of targeted therapy in metastatic triple-negative breast cancer. Breast Care (Basel) 6: 234-239, 2011.
23. Niers TM, Richel DJ, Meijers JC and Schlingemann RO: Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One 6: e19873, 2011.
24. Pang R and Poon RT: Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 242: 151-167, 2006.
25. Webber K, Cooper A, Kleiven H, Yip D and Goldstein D: Management of metastatic renal cell carcinoma in the era of targeted therapies. Intern Med J 41: 594-605, 2011.
26. Kesisis G, Kontovinis LF, Gennatas K and Kortsaris AH: Biological markers in breast cancer prognosis and treatment. J BUON 15: 447-454, 2010.
27. Klos KS, Wyszomierski SL, Sun M, et al: ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 66: 2028-2037, 2006.
28. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
29. Chien CY, Su CY, Hwang CF, et al: Clinicopathologic significance of CD105 expression in squamous cell carcinoma of the hypopharynx. Head Neck 28: 441-446, 2006.
30. Dales JP, Garcia S, Andrac L, et al: Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: Correlation with long-term patient outcome. Int J Oncol 24: 1197-1204, 2004.
31. Rau KM, Kang HY, Cha TL, Miller SA and Hung MC: The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 12: 511-532, 2005.
32. Davoli A, Hocevar BA and Brown TL: Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol 65: 611-623, 2010.
33. Roy V and Perez EA: Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist 14: 1061-1069, 2009.
34. Nam JS, Terabe M, Mamura M, et al: An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68: 3835-3843, 2007.
35. She X, Matsuno F, Harada N, Tsai H and Seon BK: Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer 108: 251-257, 2004.
36. Uneda S, Toi H, Tsujie T, et al: Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 125: 1446-1453, 2009.
37. Lee SH, Mizutani N, Mizutani M, et al: Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol Immunother 55: 1565-1574, 2006.
38. Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M and Paterson Y: Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105. Cancer Immunol Immunother 60: 931-942, 2011.
39. Foy KC, Liu Z, Phillips G, Miller M and Kaumaya PT: Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem 286: 13626-13637, 2011.